Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Angela Dispenzieri, Francis Buadi, Shaji K Kumar, Craig B. Reeder, Taimur Sher, Martha Lacy, Robert A. Kyle, Joseph R Mikhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A. Lust, David M Dingli, Ronald S. Go, Yi Lisa Hwa, Suzanne R. Hayman, Rafael Fonseca, Sikander Ailawadhi, Peter Leif BergsagelAsher A Chanan Khan, S Vincent Rajkumar, Stephen J Russell, Alexander Keith Stewart, Steven R. Zeldenrust, Morie Gertz

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

Original languageEnglish (US)
Pages (from-to)1054-1081
Number of pages28
JournalMayo Clinic Proceedings
Volume90
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Consensus
Expert Testimony
Therapeutics
Multiple Myeloma
Decision Making
Physicians
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2133504b4d99494a8a059f9586308002,
title = "Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement",
abstract = "Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.",
author = "Angela Dispenzieri and Francis Buadi and Kumar, {Shaji K} and Reeder, {Craig B.} and Taimur Sher and Martha Lacy and Kyle, {Robert A.} and Mikhael, {Joseph R} and Vivek Roy and Nelson Leung and Martha Grogan and Prashant Kapoor and Lust, {John A.} and Dingli, {David M} and Go, {Ronald S.} and Hwa, {Yi Lisa} and Hayman, {Suzanne R.} and Rafael Fonseca and Sikander Ailawadhi and Bergsagel, {Peter Leif} and {Chanan Khan}, {Asher A} and Rajkumar, {S Vincent} and Russell, {Stephen J} and Stewart, {Alexander Keith} and Zeldenrust, {Steven R.} and Morie Gertz",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2015.06.009",
language = "English (US)",
volume = "90",
pages = "1054--1081",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Treatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

AU - Dispenzieri, Angela

AU - Buadi, Francis

AU - Kumar, Shaji K

AU - Reeder, Craig B.

AU - Sher, Taimur

AU - Lacy, Martha

AU - Kyle, Robert A.

AU - Mikhael, Joseph R

AU - Roy, Vivek

AU - Leung, Nelson

AU - Grogan, Martha

AU - Kapoor, Prashant

AU - Lust, John A.

AU - Dingli, David M

AU - Go, Ronald S.

AU - Hwa, Yi Lisa

AU - Hayman, Suzanne R.

AU - Fonseca, Rafael

AU - Ailawadhi, Sikander

AU - Bergsagel, Peter Leif

AU - Chanan Khan, Asher A

AU - Rajkumar, S Vincent

AU - Russell, Stephen J

AU - Stewart, Alexander Keith

AU - Zeldenrust, Steven R.

AU - Gertz, Morie

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

AB - Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

UR - http://www.scopus.com/inward/record.url?scp=84938573654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938573654&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.06.009

DO - 10.1016/j.mayocp.2015.06.009

M3 - Article

C2 - 26250727

AN - SCOPUS:84938573654

VL - 90

SP - 1054

EP - 1081

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -